Abstract
Adenosine and its receptors play different roles in normal and patho-physiological conditions. For these reasons, many laboratories have focused their attention on dissecting the molecular pathway underlying the mechanism of action of this nucleoside with the final goal being to design new drugs. Wide expression and overlapping functions have been the major problems to designing specific adenosine agonists and antagonists with few associated negative side effects. Engineered mice have helped to dissect the single adenosine receptor function in specific tissues and pathological conditions. All these efforts in the last 20 years have led to the design of more than 2000 compounds, some of them now in clinical trials for treating different pathologies. In this review, we highlight the mouse animal models that have been of use in designing new selective drugs as well as discuss the main adenosine receptor ligands in clinical trials.
Keywords: Adenosine, adenosine receptors, animal models, clinical trials
Current Topics in Medicinal Chemistry
Title: Adenosine Receptor Ligands in Clinical Trials
Volume: 10 Issue: 10
Author(s): F. Rizzolio, R. La Montagna, T. Tuccinardi, G. Russo, M. Caputi and A. Giordano
Affiliation:
Keywords: Adenosine, adenosine receptors, animal models, clinical trials
Abstract: Adenosine and its receptors play different roles in normal and patho-physiological conditions. For these reasons, many laboratories have focused their attention on dissecting the molecular pathway underlying the mechanism of action of this nucleoside with the final goal being to design new drugs. Wide expression and overlapping functions have been the major problems to designing specific adenosine agonists and antagonists with few associated negative side effects. Engineered mice have helped to dissect the single adenosine receptor function in specific tissues and pathological conditions. All these efforts in the last 20 years have led to the design of more than 2000 compounds, some of them now in clinical trials for treating different pathologies. In this review, we highlight the mouse animal models that have been of use in designing new selective drugs as well as discuss the main adenosine receptor ligands in clinical trials.
Export Options
About this article
Cite this article as:
Rizzolio F., La Montagna R., Tuccinardi T., Russo G., Caputi M. and Giordano A., Adenosine Receptor Ligands in Clinical Trials, Current Topics in Medicinal Chemistry 2010; 10 (10) . https://dx.doi.org/10.2174/156802610791293154
DOI https://dx.doi.org/10.2174/156802610791293154 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Incidence and Prevalence of Hypothyroidism in Patients Affected by Chronic Heart Failure: Role of Amiodarone
Endocrine, Metabolic & Immune Disorders - Drug Targets Perinatal Heart Programming: Long-term Consequences
Current Medicinal Chemistry Bridging the Gap: The Potential Role of Corticosteroid Binding Globulin in Cardiac Steroid Facilitation
Current Drug Targets Gender Differences in the Effects of Angiotensin Receptor Blockers on Cardiovascular Disease
Current Pharmaceutical Design Cardiovascular Effects of Modulators of Soluble Guanylyl Cyclase Activity
Cardiovascular & Hematological Agents in Medicinal Chemistry Ventricular Arrhythmias in Seniors with Heart Failure: Present Dilemmas and Therapeutic Considerations: A Systematic Review
Current Cardiology Reviews The Interaction Between Gender and Diabetes Mellitus in the Coronary Heart Disease Risk
Current Pharmaceutical Design Molecular Imaging: Its Application In Cardiovascular Diagnosis
Current Pharmaceutical Design Role of PI3 Kinase Gamma in Excitation-Contraction Coupling and Heart Disease
Cardiovascular & Hematological Disorders-Drug Targets Autophagy in Chronic Myeloid Leukaemia: Stem Cell Survival and Implication in Therapy
Current Cancer Drug Targets Doxorubicin Loaded Dextran-coated Superparamagnetic Iron Oxide Na-noparticles with Sustained Release Property: Intracellular Uptake, Phar-macokinetics and Biodistribution Study
Current Pharmaceutical Biotechnology Cutaneous Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Pharmacy and Exercise as Complimentary Partners for Successful Cardiovascular Ageing
Current Vascular Pharmacology The Two Faces of Iminoalditols: Powerful Inhibitors Trigger Glycosidase Activation
Current Enzyme Inhibition Polyamines and Related Nitrogen Compounds in the Chemotherapy of Neglected Diseases Caused by Kinetoplastids
Current Topics in Medicinal Chemistry Stem Cells as a Novel Tool for Drug Screening and Treatment of Degenerative Diseases
Current Pharmaceutical Design Heat Shock Proteins - Two Sides of a Coin
Current Cardiology Reviews Regulatory Roles of the Ubiquitin-Proteasome System in Cardiomyocyte Apoptosis
Current Molecular Medicine Atrial Tachycardias Arising from the Atrial Appendages and Aortic Sinus of Valsalva
Current Cardiology Reviews Cardiac Regeneration by Progenitor Cells: What Is It Known as and What Is It Still to Be Known as?
Cardiovascular & Hematological Agents in Medicinal Chemistry